Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon/Sanofi Arixtra Late January Launch Will Be Supported By 240 Reps

Executive Summary

Organon and Sanofi-Synthelabo will launch the injectable antithrombotic Arixtra with 240 sales reps in late January

You may also be interested in...



Sanofi Buys Out Arixtra Joint Venture With Organon; Expanded Label Coming

Sanofi-Synthelabo is taking over sole rights to Arixtra from Organon ahead of an expected label expansion for the antithrombotic agent

Sanofi Buys Out Arixtra Joint Venture With Organon; Expanded Label Coming

Sanofi-Synthelabo is taking over sole rights to Arixtra from Organon ahead of an expected label expansion for the antithrombotic agent

Sanofi/Organon Arixtra

Arixtra added to 425 hospital formularies in the U.S. and Europe as of July, Sanofi says. Sanofi/Organon launched Arixtra (fondaparinux) for deep vein thrombosis in the first quarter (1"The Pink Sheet" Dec. 17, 2001, p. 3). While Arixtra sales had a slow start in the first half, "formulary wins are in line with expectations," Sanofi said. The company expects Arixtra to gain full access to the low molecular weight heparin market in 2006; Sanofi estimates its approved use in hospital-based orthopedic surgery provides 14% access...

Related Content

UsernamePublicRestriction

Register

PS039019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel